Introduction to ECRSwNP and Metabolic Dysregulation

Eosinophilic chronic rhinosinusitis with nasal polyps (ECRSwNP) represents a particularly challenging phenotype of respiratory disease. It is often characterized by intense type 2 inflammation, severe edema, and significant ECRSwNP mucosal remodeling. While clinicians have long recognized the role of cytokines like IL-4 and IL-13, the specific metabolic pathways driving tissue changes remained elusive. Recent research now highlights a critical link between arachidonic acid metabolism and the structural changes seen in nasal polyps.

The Role of ALOX15 in ECRSwNP Mucosal Remodeling

Investigators have identified a specific metabolic axis involving arachidonate 15-lipoxygenase (ALOX15) and its metabolite, 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE]. When IL-4 and IL-13 levels rise during type 2 inflammation, they induce ALOX15 expression. Consequently, this enzyme converts arachidonic acid into 15(S)-HETE. This metabolite then activates the peroxisome proliferator-activated receptor gamma (PPAR-γ). Furthermore, this activation directly suppresses transforming growth factor-β1 (TGF-β1), which is essential for healthy collagen production. Because TGF-β1 levels drop, the nasal mucosa fails to maintain structural integrity, leading to the exacerbated edema typical of the disease.

Therapeutic Implications for Refractory Polyps

Targeting this metabolic pathway offers a promising strategy for managing refractory cases. In animal models, inhibiting ALOX15 effectively improved ECRSwNP mucosal remodeling, reduced polyp size, and lowered inflammatory markers. Similarly, clinical data suggests that anti-IL-4Rα monoclonal antibody treatment can reverse this metabolic imbalance. By blocking the upstream signals of IL-4 and IL-13, these therapies help restore the ALOX15-15(S)-HETE-PPAR-γ axis to a more balanced state. Therefore, clinicians might soon utilize metabolic markers to predict treatment responses or select personalized biologic therapies for patients with severe eosinophilic disease.

Frequently Asked Questions

How does 15(S)-HETE influence ECRSwNP mucosal remodeling?

15(S)-HETE activates PPAR-γ, which subsequently suppresses TGF-β1. This suppression leads to reduced collagen production and increased tissue edema, impairing the natural remodeling process of the nasal mucosa.

Can existing biologics target this metabolic axis?

Yes, treatments such as anti-IL-4Rα monoclonal antibodies work by inhibiting the cytokines that induce ALOX15. By reducing these upstream signals, the biologics help normalize the 15(S)-HETE levels and improve tissue structure.

Why is ALOX15 significant in eosinophilic nasal polyps?

ALOX15 serves as a bridge between inflammation and metabolism. Its upregulation in response to type 2 cytokines makes it a key driver of the metabolic dysregulation that causes polyps to persist and recur.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Li Y et al. Type 2 Inflammation-Biased Arachidonic Acid Metabolite Regulates Mucosal Remodeling of Chronic Rhinosinusitis With Nasal Polyps. Allergy. 2026 Mar 17. doi: 10.1111/all.70301. PMID: 41841346.

Li Y, Yan B, Cui B, Wang C. Predictive significance of 15(S)-hydroxyeicosatetraenoic acid for eosinophilic chronic rhinosinusitis with nasal polyps. Asia Pac Allergy. 2025;15(2):e187. doi: 10.5415/apallergy.0000000000000187.

Sulem P et al. A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis. Nat Genet. 2019;51(2):267-276. doi: 10.1038/s41588-018-0314-6.